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Pseudoxanthoma elasticum is a heritable disorder of connective tissue characterized by cutaneous,
vascular and ocular changes that result from the accumulation of fragmented elastic fibres. Even though
the etiopathogenesis is not still completely understood, in recent years in literature some Authors have
considered pseudoxanthoma elasticum as a metabolic disorder. We present the case of a 45-year-old man
affected by pseudoxanthoma elasticum and light-chain amyloidosis and we discuss the possible reasons
that led to this association.
We report the case of a 45-year-old man who
presented pseudoxanthoma elasticum, associated
with light-chain amyloidosis. This association
is quite rare, even though in literature there are
a few cases reported. This study would like to
stress and underline the importance of considering
pseudoxanthoma e1asticum as a metabolic disorder
and not as a primary elastic disorder. Moreover,
we would like to underline the importance of
considering that pseudoxanthoma elasticum could
favour amyloidogenesis and fibril stabilization.
MATERIALS AND METHODS
A 45-year-old Caucasian Italian man was admitted to
our hospital for the onset of progressively less exertion
dyspnea and lower limb edema. A complete medical
history was taken and general physical examination was
performed. A complete familial medical history was
performed. Routine laboratory tests included complete
blood count, erythrocyte sedimentation rate, routine
biochemistry. Echocardiographic and electrocardiographic
tests were carried out, in addition to a cardiac MRI. A bone
marrow biopsy, an accessory salivary gland biopsy and a
skin biopsy of the affected area were taken. The material
was fixed in formalin and embedded in paraffin. Routine
histologic skin sections were stained with Hematoxylin-
eosin, Weigert stain and red Congo stain.
RESULTS
History
In May 2011, a 45-year old man was admitted
to our hospital for the onset of progressively less
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exertion dyspnea and lower limb edema.
Laboratory examinations
Hematochemical and instrumental tests showed a
red blood cell count at the lower limit ofnormal range,
hypoalbuminemia (2.7 g/dl) and a proteinuria of 2.7
g/24 h. Further investigations revealed monoclonal
lambda light-chain component in serum and a Bence-
Jones lambda type proteinuria. Echocardiographic
and electrocardiographic tests were carried out, in
addition to a cardiac MRI, the findings of which
suggested a restrictive cardiomiopathy of infiltrative
type.
Physical examination
Cutaneous examination revealed small, yellowish,
non-pruriginous papules coalescing into plaques,
located on the periorbital region, the neck, the trunk
and the groin. Oculistic examination excluded the
presence of angioid streaks of the retina.
Histological examination and immunohistochemical
assay
A bone marrow biopsy showed a plasmacellular
infiltrate rate of 20% of the total bone-marrow cell
population and focal areas of amyloid deposits.
An accessory salivary gland biopsy was made,
confirming the presence of amyloid deposits. Skin
biopsy of a papule of the trunk highlighted aberrant
somewhat calcified, clumped and fragmented
elastic fibers in the mid-dermis, compatible with
the diagnosis of pseudoxanthoma elasticum. (Figs.
Ia and 2b). Numerous, small, distorted elastic fibers
were seen and the red Congo stain was negative for
the presence of substance amiloidea (Fig. 2 a and b).
Diagnosis, treatment and clinical course
The diagnosis of light-chain amyloidosis with
cardiac involvement was finally made, unusually
associated with pseudoxanthoma elasticum.
The patient was immediately treated with
cyclophosphamide 500 mg weekly and bortezomib
1.3 mg/m? twice a week (CYBORD). After two
chemotherapy cycles no improvement was observed
in the patient's conditions and the rapid worsening
of cardiac functions led to the patient's death for a
cardiac arrest.
DISCUSSION
The association between pseudoxanthoma
elasticum (PXE) and light-chain amyloidosis
(AL-amyloidosis) is rarely described in literature
and only two other cases of PXE, associated with
Familiar Mediterranean fever-related amyloidosis
(FMF-amyloidosis) are reported (1-2). PXE is a
multisystem heritable disorder, characterized by
ectopic mineralization of peripheral connective
tissue, with particular involvement of elastic
fibers, affecting primarily the skin, the eyes and
Fig. 1. a, b) Pseudoxanthoma elasticum (a: 25X, hematoxylin-eosin; b: 200x hematoxylin-eosin).
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Fig. 2. a) Pseudoxanthoma elasticum a.200X Weigert stain . Numerous, small, distorted elastic fib ers are seen. b) The red
Congo stain is negative for the presence ofsubstance amiloidea.
cardiovascular system (3). The precise prevalence
of PXE is currently unknown, but is estimated
to be around one in 50,000 (3). Some cases have
only skin manifestations, other have only eyes or
cardiovascular involvement, suggesting that the
role of additional variables like epigenetics, dietary
factors and life style need to be considered.
Cutaneous lesions are yellowish papules (4), and
histological features show fragmented, basophilic
and calcified elastic fibers in mid-dermis, known as
"elastorrhexia", observed also in apparently normal
skin. To date PXE has been considered a primary
disorder of elastic fibers.
In some cases, the genetic mutations in PXE involve
the ABCC6 gene, which encodes a transmembrane
transporter protein, expressed primarily in the liver
and the kidneys, organs not known to be affected by
the disease (5-6-7). The exact function of the ABCC6
protein is not completely understood. All these
observations would suggest that PXE is not a primary
disorder ofelastic fibers but a metabolic condition (8).
AL-amyloidosis is the most common form of
systemic amyloidosis and clinically presents with
cardiac involvement in 50% of cases (9), with an
incidence of 8 to 10 cases per million person-years, a
median age at diagnosis of 63, and a median survival
time if left untreated of 12 months. Systemic light-
chain amyloidosis (AL) is caused by misfolded
immunoglobulin light-chain proteins that aggregate
and deposit as unique fibrils, ultimately leading to
organ failure and death . Tissue biopsy, either of an
involved organ or a surrogate site (e.g., abdominal
fat), must demonstrate amyloid deposition by classic
Congo red staining or electron microscopy. For
typing, immunohistochemical staining is frequently
unreliable and inaccurate, and immunogold electron
microscopy is reliable but limited by serologic
dependence (1-2).
Regarding the unusual association of PXE and
AL-amyloidosis, the link, supposed between these
two diseases, is not yet completely understood
and can not explain the rarity of their concurrent
manifestation. Some Authors have reported in
literature that PXE could favour amyloidogenesis
and amyloid fibril stabilization, in fact in PXE there
is an increased production of glycosaminoglycans,
especially heparan sulphate, that colocalize with
amyloid proteins (10). In accordance with Cattan et
al., the changes in glycosaminoglican metabolism
present in PXE, could lead to a worsening of AAL-
amyloidosis. This fact values Uitto's hypothesis
that PXE can be considered a metabolic disorder.
Moreover, other genes, still unknown , are probably
involved. Therefore we can conclude that PXE is
the result of a metabolic disorder induced by genetic
alteration and other acquired factors. This framework
explains the existence ofpatients predominantly with
skin involvement and patients with organ system
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involvement. We describe this case report for its
rarity and its particular nosographic interest; further
studies, however, are necessary to increase knowledge
on diagnosis, pathomechanisms and treatment of
PXE and to find new possible correlations between
these two pathologic conditions.
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